ATE263760T1 - 3-amino-2,2-di-c-alkyl-1,4-butyrolactone und n- substituierte 1,4-thiobutyrolactone die zur stimulation der gamma-aminobutansäureaktivität und zur behandlung von nervenerkrankungen verwendung finden, sowie verfahren zu ihrer herstellung - Google Patents

3-amino-2,2-di-c-alkyl-1,4-butyrolactone und n- substituierte 1,4-thiobutyrolactone die zur stimulation der gamma-aminobutansäureaktivität und zur behandlung von nervenerkrankungen verwendung finden, sowie verfahren zu ihrer herstellung

Info

Publication number: ATE263760T1
Authority: AT; Austria
Prior art keywords: alkyl; group; thiobutyrolactone; butyrolactone; amino
Prior art date: 1999-10-22

Application number

AT00969660T

Other languages

English (en)

Inventor

Robert Dodd

Hadri Ahmed El

Pierre Jean-Paul Potier

Werner Sieghart

Frantisek Jursky

Roman Furtmuller

Erwin Sigel

Urs Thomet

Original Assignee

Centre Nat Rech Scient

Innovationsagentur Gmbh Bu Tec

Univ Bern

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-22

Filing date

2000-10-20

Publication date

2004-04-15

2000-10-20 Application filed by Centre Nat Rech Scient, Innovationsagentur Gmbh Bu Tec, Univ Bern filed Critical Centre Nat Rech Scient

2004-04-15 Application granted granted Critical

2004-04-15 Publication of ATE263760T1 publication Critical patent/ATE263760T1/de

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
KMSNYNIWEORQDJ-UHFFFAOYSA-N Dihydro-2(3H)-thiophenone Chemical compound O=C1CCCS1 KMSNYNIWEORQDJ-UHFFFAOYSA-N 0.000 title 1
239000002253 acid Substances 0.000 title 1
201000010099 disease Diseases 0.000 title 1
230000000694 effects Effects 0.000 title 1
210000005036 nerve Anatomy 0.000 title 1
230000004936 stimulating effect Effects 0.000 title 1
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
125000004430 oxygen atom Chemical group O* 0.000 abstract 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

AT00969660T 1999-10-22 2000-10-20 3-amino-2,2-di-c-alkyl-1,4-butyrolactone und n- substituierte 1,4-thiobutyrolactone die zur stimulation der gamma-aminobutansäureaktivität und zur behandlung von nervenerkrankungen verwendung finden, sowie verfahren zu ihrer herstellung ATE263760T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9913233A FR2800069A1 (fr)	1999-10-22	1999-10-22	3-amino-2,2-di-c-alkyl-1,4-butyrolactones et 1,4- thiobutyrolactones n-substituees utiles comme stimulant de l'activite de l'acide gamma-aminobutyrique et leur procede de preparation
PCT/FR2000/002928 WO2001029017A2 (fr)	1999-10-22	2000-10-20	3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES ET 1,4-THIOBUTYROLACTONES N-SUBSTITUEES UTILES COMME STIMULANT DE L'ACTIVITE DE L'ACIDE η-AMINOBUTYRIQUE ET DANS LE TRAITEMENT DES TROUBLES NERVEUX ET LEUR PROCEDE DE PREPARATION

Publications (1)

Publication Number	Publication Date
ATE263760T1 true ATE263760T1 (de)	2004-04-15

Family

ID=9551262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00969660T ATE263760T1 (de)	1999-10-22	2000-10-20	3-amino-2,2-di-c-alkyl-1,4-butyrolactone und n- substituierte 1,4-thiobutyrolactone die zur stimulation der gamma-aminobutansäureaktivität und zur behandlung von nervenerkrankungen verwendung finden, sowie verfahren zu ihrer herstellung

Country Status (9)

Country	Link
US (1)	US6660769B1 (de)
EP (1)	EP1226133B1 (de)
JP (1)	JP2003512363A (de)
AT (1)	ATE263760T1 (de)
AU (1)	AU7932100A (de)
CA (1)	CA2387974A1 (de)
DE (1)	DE60009739T2 (de)
FR (1)	FR2800069A1 (de)
WO (1)	WO2001029017A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8193363B2 (en) *	2008-08-29	2012-06-05	Astrazeneca Ab	Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3968233A (en) *	1973-12-05	1976-07-06	Istituto Chemioterapico Italiano	α-Amino-γ-butyrolactones as sedatives
IT1183053B (it) *	1984-02-02	1987-10-05	Farmaceutico Ct Lab	Derivati dell'alfa-amino-gamma-butirrolatton e, metodo per prepararli e composizioni farmaceutiche che li contengono
US4707491A (en)	1985-12-20	1987-11-17	Washington University	Anticonvulsant γ-thiobutyrolactone derivatives
US5719057A (en)	1991-06-11	1998-02-17	Merck Sharpe & Dohme Ltd.	Stably human transfected rodent fibroblast cell line expressing human GABA-A recepotors, and cloned human GABA-A receptor subunit CDNA sequences

1999
- 1999-10-22 FR FR9913233A patent/FR2800069A1/fr not_active Withdrawn
2000
- 2000-10-20 JP JP2001531817A patent/JP2003512363A/ja active Pending
- 2000-10-20 CA CA002387974A patent/CA2387974A1/fr not_active Abandoned
- 2000-10-20 AT AT00969660T patent/ATE263760T1/de not_active IP Right Cessation
- 2000-10-20 WO PCT/FR2000/002928 patent/WO2001029017A2/fr not_active Ceased
- 2000-10-20 DE DE60009739T patent/DE60009739T2/de not_active Expired - Fee Related
- 2000-10-20 EP EP20000969660 patent/EP1226133B1/de not_active Expired - Lifetime
- 2000-10-20 AU AU79321/00A patent/AU7932100A/en not_active Abandoned
- 2000-10-20 US US10/111,091 patent/US6660769B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6660769B1 (en)	2003-12-09
JP2003512363A (ja)	2003-04-02
CA2387974A1 (fr)	2001-04-26
FR2800069A1 (fr)	2001-04-27
EP1226133A2 (de)	2002-07-31
DE60009739D1 (de)	2004-05-13
AU7932100A (en)	2001-04-30
DE60009739T2 (de)	2005-05-12
WO2001029017A3 (fr)	2001-12-13
EP1226133B1 (de)	2004-04-07
WO2001029017A2 (fr)	2001-04-26

Similar Documents

Publication	Publication Date	Title
FR2809396B1 (fr)	2005-10-14	Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
EA200600294A1 (ru)	2006-08-25	[1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
DE3765864D1 (de)	1990-12-06	N-phosphonylmethoxyalkyl-derivate von pyrimidin- und purinbasen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen mit antiviraler wirkung, die sie enthalten.
DE59807405D1 (de)	2003-04-10	Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende mittel und verfahren zu ihrer herstellung
NO994452D0 (no)	1999-09-14	Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
DE60011462D1 (de)	2004-07-15	Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
DE3867403D1 (de)	1992-02-13	L-dopa-derivate oder ihre saeureadditionssalze, verfahren zu ihrer herstellung und ihre verwendung.
ATE497950T1 (de)	2011-02-15	Isochinolin-1,3,4-trion, synthetisches verfahren und dessen verwendung
ATE211474T1 (de)	2002-01-15	Galanthamin derivate, verfahren zu ihrer herstellung und ihre verwendung als medikamente
DE69837564D1 (de)	2007-05-24	Azaheterozyklischederivate zur behandlung von haarausfall und neurologischer krankheiten
DE60004671D1 (de)	2003-09-25	Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
DE3681690D1 (de)	1991-10-31	N-substituierte 3-piperidin- oder 3-pyridincarbonsaeuren und deren derivate.
ATE194851T1 (de)	2000-08-15	Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
ATE145903T1 (de)	1996-12-15	Kondensierte chinolyl-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln zur behandlung von herz- kreislauferkrangen
DE3774273D1 (de)	1991-12-05	Chinazolin-derivat, verfahren zu dessen herstellung und mittel zur behandlung von cerebraler disfunktion als aktiver inhaltsstoff.
ATE263760T1 (de)	2004-04-15	3-amino-2,2-di-c-alkyl-1,4-butyrolactone und n- substituierte 1,4-thiobutyrolactone die zur stimulation der gamma-aminobutansäureaktivität und zur behandlung von nervenerkrankungen verwendung finden, sowie verfahren zu ihrer herstellung
FR2763335B1 (fr)	2000-11-24	Nouveaux composes heterocycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE114468T1 (de)	1994-12-15	Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
ATE152709T1 (de)	1997-05-15	Tetrahydrocyclopent(b>indole-methanamine und verwandte verbindungen, und verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE334680T1 (de)	2006-08-15	4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
DE50311420D1 (de)	2009-05-28	2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
ATE283838T1 (de)	2004-12-15	Wirksame derivate der valproinsäure zur behandlung von neurologischen und psychotischen störungen, und ein verfahren zu ihrer herstellung
ATE245155T1 (de)	2003-08-15	N-substituierte 1-(butyrolacton)-isochinoline zur behandlung von nervenstörungen
ATE421961T1 (de)	2009-02-15	Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
ATE214375T1 (de)	2002-03-15	Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung

Legal Events

Date	Code	Title	Description
2004-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties